GlassScriptPhysician profile
Daniel Rzepka
NPI 1598861312
$3,067.15
in general payments reported to CMS, 2019-2025
31 companies · $410 in 2025
The $410 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $217 · 2021: $417 · 2022: $382 · 2023: $705 · 2024: $407 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,402 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,401.92 |
| Education | $120.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $597.80 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Astellas Pharma US INC | $406.63 | 2022-2025 | Veozah |
| Pfizer INC. | $216.43 | 2022-2025 | |
| Therapeuticsmd, INC. | $151.66 | 2019-2021 | |
| Lupin INC. | $140.79 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $136.06 | 2023-2025 | |
| Ethicon US, LLC | $133.40 | 2022-2025 | Surgicel Nu-Knit, Surgiflo Hemostatic Matrix, Ethicon |
| Evofem Biosciences, INC. | $127.87 | 2021-2022 | |
| Roche Diagnostics Corporation | $125.00 | 2019 | |
| Organon LLC | $123.24 | 2023-2025 | Nexplanon, Jada System |
| Merck Sharp & Dohme LLC | $98.65 | 2019-2025 | Gardasil 9, Gardasil, Bridion |
| Bayer Healthcare Pharmaceuticals INC. | $98.41 | 2021-2024 | |
| Agile Therapeutics, INC. | $97.41 | 2021-2023 | Twirla |
| Sage Therapeutics, LLC | $79.09 | 2024-2025 | Zurzuvae |
| Exeltis, USA INC. | $72.89 | 2022-2024 | Slynd |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $58.49 | 2019-2025 | |
| Novo Nordisk INC | $52.74 | 2019-2021 | |
| Millicent US INC | $50.39 | 2024 | Femring, Intrarosa |
| Hologic Sales and Service, LLC | $43.61 | 2020-2025 | Myosure Tissue Removal Device, Fluent Fluid Management System, Novasure |
| Sumitomo Pharma America, INC. | $37.03 | 2023-2025 | Gemtesa, Myfembree |
| Coopersurgical, INC. | $32.28 | 2019-2023 | Paragard T 380a |
| Amgen INC. | $30.28 | 2019 | |
| Mylan Pharmaceuticals INC. | $27.14 | 2019 | |
| Exact Sciences Corporation | $25.48 | 2025 | Cologuard Collection Kit |
| Myovant Sciences INC. | $20.33 | 2022 | |
| Optumhealth Care Solutions, LLC | $16.82 | 2023 | Zyno Solutions, Vivify Health Care Team Portal |
| Meditrina | $15.77 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.66 | 2022 | |
| Karl Storz Endoscopy-America | $13.44 | 2024 | Hopkins |
| Allergan, INC. | $11.87 | 2019 | |
| Duchesnay USA Incorporated | $11.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Rzepka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.